
    
      This was a two stage, controlled, open-label trial. Stage I of the trial simulated
      meningococcal challenge Stage II of the trial evaluated the meningococcal vaccine naïve
      participants from Stage I, who had also received a reduced dose of Menomune® vaccine in Stage
      I and were administered a full dose of Menactra® vaccine 6 months later.
    
  